Mufg Securities Americas Inc. Takes $2.94 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Mufg Securities Americas Inc. purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 5,647 shares of the medical research company’s stock, valued at approximately $2,938,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in TMO. MainStreet Investment Advisors LLC bought a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $233,000. Malaga Cove Capital LLC lifted its holdings in Thermo Fisher Scientific by 56.4% in the fourth quarter. Malaga Cove Capital LLC now owns 1,722 shares of the medical research company’s stock valued at $896,000 after buying an additional 621 shares during the period. Nia Impact Advisors LLC grew its holdings in Thermo Fisher Scientific by 12.1% during the 4th quarter. Nia Impact Advisors LLC now owns 10,184 shares of the medical research company’s stock worth $5,298,000 after acquiring an additional 1,100 shares during the period. Nomura Holdings Inc. lifted its stake in shares of Thermo Fisher Scientific by 179.1% in the 4th quarter. Nomura Holdings Inc. now owns 15,427 shares of the medical research company’s stock valued at $8,026,000 after purchasing an additional 9,899 shares during the period. Finally, Nearwater Capital Markets Ltd acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at about $10,405,000. Institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. This trade represents a 25.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the transaction, the chief executive officer now directly owns 115,174 shares in the company, valued at approximately $59,506,950.58. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,075 shares of company stock valued at $7,305,942 over the last ninety days. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Down 0.9%

Shares of Thermo Fisher Scientific stock opened at $428.88 on Wednesday. The stock has a market cap of $161.90 billion, a P/E ratio of 25.95, a P/E/G ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 12-month low of $401.75 and a 12-month high of $627.88. The business’s 50 day moving average is $460.85 and its 200-day moving average is $513.11. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same period in the previous year, the business earned $5.11 EPS. Thermo Fisher Scientific’s revenue for the quarter was up .2% compared to the same quarter last year. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. Thermo Fisher Scientific’s payout ratio is presently 10.09%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on TMO shares. Royal Bank of Canada cut their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Wednesday, April 23rd. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, April 24th. Evercore ISI cut their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Finally, UBS Group lowered their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a research note on Thursday, April 24th. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $607.43.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.